PCI Biotech Holding ASA (FRA:4QG)
€ 0.1288 0.0022 (1.74%) Market Cap: 5.10 Mil Enterprise Value: 2.59 Mil PE Ratio: 0 PB Ratio: 1.76 GF Score: 41/100

Q1 2020 PCI Biotech Holding ASA Earnings Call Transcript

May 06, 2020 / 06:30AM GMT
Release Date Price: €4.87 (-9.91%)
Operator

Good morning, and welcome to this first quarter 2020 presentation for PCI Biotech. My name is Per Walday, and I'm the CEO of PCI Biotech. I have with me also Ronny Skuggedal, who is the CFO for PCI Biotech.

We will start this presentation that due to the COVID-19 pandemic is only done through a webcast this time, by going through the background of the company, a bit on the technology, then some highlights for the quarter and then a more detailed look into the different programs and to end up when -- with the outlook. And we will open up -- we are opening up also for questions now from the webcast, and you can start submitting questions already now if you want to do that.

So let's move into the presentation and to start to talk a little bit about PCI Biotech, what we are.

So we are a company -- biotech company, developing technology that was invented at the Radium Hospital. It's called photochemical internalization. That's why it's called PCI Biotech. Photochemical internalization is a platform technology that can be used for a number of different applications. We are focusing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot